A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market

A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market

Launch of Novel Immunoglobulin Products and Increasing Awareness of Therapeutic Options to Drive Double-digit Market Growth

RELEASE DATE
08-Dec-2015
REGION
Asia Pacific
Research Code: MAEC-01-00-00-00
SKU: LS00108-AP-MR_16949

$6,000.00

Special Price $4,500.00 save 25 %

In stock
SKU
LS00108-AP-MR_16949

$6,000.00

$4,500.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges.

Table of Contents

Executive Summary

Recent Market Developments

Key M&As and Partnership Assessment

Companies to Watch

Methodology and Scope

Market Background—Segmentation

Market Background—Segmentation (continued)

Market Background—Segmentation (continued)

Market Segmentation

Market Segmentation (continued)

Market Forecasting

Competitive Landscape—Human Plasma-derived Therapeutics: Marketed Products

Competitive Landscape—Human Plasma-derived Therapeutics Market: Pipeline Products

Competitive Landscape—Count of Marketed and Pipeline Products

Competitive Landscape—Key Clinical Trials

Marketed Products Synopsis—Albumin

Marketed Products Synopsis—Other Haematologicals

Marketed Products Synopsis—Other Haematologicals (continued)

Marketed Products Synopsis—Coagulation Factors

Marketed Products Synopsis—Coagulation Factors (continued)

Marketed Products Synopsis—Coagulation Factors (continued)

Marketed Products Synopsis—Coagulation Factors (continued)

Marketed Products Synopsis—Immunoglobulins

Marketed Products Synopsis—Immunoglobulins (continued)

Marketed Products Synopsis—Immunoglobulins (continued)

Marketed Products Synopsis—Immunoglobulins (continued)

Marketed Products Synopsis—Immunoglobulins (continued)

Marketed Products Synopsis—Immunoglobulins (continued)

Pipeline Analysis—Approved

Pipeline Analysis—Phase 3

Pipeline Analysis—Phase 3 (continued)

Pipeline Analysis—Phase 2

Pipeline Analysis—Phase 1

Product Dashboard—ResusixTM, Entegrion, Inc.

Product Dashboard—CINRYZE® (new formulation), Shire

Product Dashboard—BIOSTATE® (new formulation), CSL Behring

Product Dashboard—Gammagard, Baxter

Conclusions and Recommendations

Legal Disclaimer

Plasma—Overview

Plasma—Overview (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The Chinese pharmaceutical market is expected to be the third-largest in the world in 2013. This research service analyzes various aspects of the Chinese pharmaceutical market between 2007 and 2016. Rising income, improving healthcare infrastructure, and insurance systems are some factors that drive this market. The study discusses in detail the market challenges and opportunities, competitive analysis, offers a revenue forecast, and a list of local company profiles along with their revenue.
More Information
No Index No
Podcast No
Author Sumedha Pareek
WIP Number MAEC-01-00-00-00
Is Prebook No